May 6th 2024
Investigators analyzed data from the Center for International Blood and Marrow Transplant Research who underwent autologous or allogeneic transplants.
Patient, Provider, and Caregiver Connection: Addressing Pediatric and AYA Patient Concerns While Managing Hodgkin Lymphoma
View More
Patient, Provider, and Caregiver Connection™: Individualizing Care for Patients with Schizophrenia—Understanding Patient Challenges and the Role of Innovative Treatment
View More
Improving Outcomes in Autoimmune Hemolytic Anemias at the Intersection Between Hematology and Oncology Care
View More
B-Cell Tumor Board: Rendering Real World Personalized Treatment Plans in CLL/SLL and MCL Through the Lens of Emerging BTKi Evidence
View More
Applying New Evidence in Multiple Myeloma Care from Frontline to R/R Disease
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
Translating New Evidence into Treatment Algorithms from Frontline to R/R Multiple Myeloma: How the Experts Think & Treat
View More
Medical Crossfire: How Has Iron Supplementation Altered Treatment Planning for Patients with Cancer-Related Anemia?
View More
Medical Crossfire®: The Experts Bridge Recent Data in Chronic Lymphocytic Leukemia With Real-World Sequencing Questions
View More
Community Practice Connections™: Pre-Conference Workshop on Immune Cell-Based Therapy
View More
Study of BMT-CARE Finds Coping, Self-Efficacy to Improve QOL, Mood in Caregivers of HSCT Recipients
October 23rd 2020According to researchers, this study suggests “that the improvements in QOL and mood experienced by caregivers assigned to BMT-CARE are, in part, explained by an acquisition of effective coping skills and confidence in their ability to provide care for their loved one.”
Single-dose BIVV001 Appears Safe, Effective for Men with Severe Hemophilia A
October 3rd 2020The study found that high levels of sustained factor VIII activity, which followed a normalization period after BIVV001 administration, might offer better protection against all types of bleeding and a longer interval between administration of the product in this patient population.
FDA Issues Complete Response Letter for Remestemcel-L to Treat Pediatric GVHD
October 2nd 2020Mesoblast Limited announced that the FDA issued a complete response letter regarding its biologics license application for remestemcel-L to treat pediatric patients with SR-aGVHD after the ODAC voted 9:1 in favor of the available efficacy and data.
Study Identifies Factors Influencing Variability in Postthaw Product Quality of Donor Stem Cells
September 17th 2020Researchers indicated these study findings “could be a note of caution for transplant centers to not take for granted that the frozen product they have received will show perfect recovery once thawed.”
sBLA Submitted Seeking Approval of Daratumumab, Hyaluronidase-fihj Combo for AL Amyloidosis
September 11th 2020The supplemental biologics license application is seeking approval for the treatment of patients with light chain amyloidosis and is supported by results observed in the phase 3 ADROMEDA study.
Constantine Si Lun Tam, MD, MBBS, FRACP, FRCPA, on the Phase 3 ASPEN Trial
June 23rd 2020Results from the trial indicated that zanubrutinib was associated with a higher complete response or very good partial response rate and demonstrated clinically meaningful advances in safety and tolerability in patients with Waldenström macroglobulinemia.
Guillermo Garcia-Manero, MD, on Eprenetapopt-Azacytidine Combo in TP53+ MDS
June 18th 2020The MD Anderson expert discussed the phase 3 trial – designed to evaluate frontline eprenetapopt in combination with azacytidine (Vidaza) in patients with TP53-mutant positive myelodysplastic syndrome (MDS) – that recently completed full enrollment.
SF3B1 Variant in MDS Found to Identify Distinct Disease Entities
May 17th 2020An international working group of experts in myelodysplastic syndromes proposed the recognition of the SF3B1 variant as a distinct nosologic entity based on the presence of a non-inheritable genetic mutation that causes the disease.